Previous studies proved that CDK1 was a diagnosis biomarker for several cancers; we predicted the diagnostic value of CDK1 in renal cancer, liver cancer, pancreatic cancer, and lung cancer from online database; the results showed that CDK1 was a good prognostic biomarker (P < 0.01; Figure 4(e)). This evidence concerns the gene CDK1 and renal carcinoma.